Full-length HIV-1 gag determines protease inhibitor susceptibility within in-vitro assays

AIDS

Volumn 24, Issue 11, 2010, Pages 1651-1655

  Gupta, Ravindra K ^a   Kohli, Arinder ^a   McCormick, Adele L ^a   Towers, Greg J ^a   Pillay, Deenan ^a,b   Parry, Chris M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

gag; HAART; HIV; protease inhibitors; subtype

Indexed keywords

ATAZANAVIR; DARUNAVIR; GAG PROTEIN; LOPINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CHIMERA; COMPARATIVE STUDY; CONTROLLED STUDY; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE;

DRUG RESISTANCE, VIRAL; GENES, GAG; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PYRIMIDINONES; VIRUS REPLICATION;

EID: 77954324656     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283398216     Document Type: Article

References (16)

1. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
2. Bally F, Martinez R, Peters S, Sudre P, Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 2000; 16:1209-1213.
3. Cote HC, Brumme ZL, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, rito-navir, and/or saquinavir. J Virol 2001; 75:589-594.
4. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996; 70:3763-3769.
5. Malet I, Roquebert B, Dalban C, Wirden M, Amellal B, Agher R, et al. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 2007; 54:367-374.
6. Parry CM, Kohli A, Boinett CJ, Towers GJ, McCormick AL, Pillay D. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol 2009; 83:9094-9101.
7. Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, Nagashima K, et al. Amino acid substitutions in Gag protein at noncleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 2002; 277:5952-5961.
8. Myint L, Matsuda M, Matsuda Z, Yokomaku Y, Chiba T, Okano A, et al. Gag noncleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:444-452.
9. Rodenburg CM, Li Y, Trask SA, Chen Y, Decker J, Robertson DL, et al. Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 2001; 17:161-168.
10. Ndung?u T, Renjifo B, Essex M. Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone. J Virol 2001; 75:4964-4972.
11. Gao F, Vidal N, Li Y, Trask SA, Chen Y, Kostrikis LG, et al. Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. AIDS Res Hum Retroviruses 2001; 17:675-688.
12. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002; 7:165-174.
13. Naeger LK, Struble KA. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS 2006; 20:847-853.
14. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
15. Kempf DJ, King MS, Bernstein B, CernohousP, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.
16. Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamo-nica P, et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir mono-therapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53:2934-2939.